



Universiteit
Leiden
The Netherlands

Exploiting HLA-alloreactivity in TCR gene therapy of B cell malignancies

Jahn, L.

Citation

Jahn, L. (2017, April 19). *Exploiting HLA-alloreactivity in TCR gene therapy of B cell malignancies*. Retrieved from <https://hdl.handle.net/1887/48861>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/48861>

Note: To cite this publication please use the final published version (if applicable).

**Exploiting HLA-alloreactivity in TCR Gene Therapy
of B Cell Malignancies**

Lorenz Jahn

Exploiting HLA-alloreactivity in TCR Gene Therapy of B Cell Malignancies
© 2017 Lorenz Jahn, New York

Cover Image: Copyright © 2009 Martin Handford
From WHERE'S WALLY? THE INCREDIBLE PAPER CHASE by
Martin Handford
Reproduced by kind permission of Walker Books Ltd,
London SE11 5HJ

Printing: Ipskamp Drukkers, Enschede, The Netherlands

ISBN: 978-94-028-0555-0

The research described in this thesis was supported by the financial assistance of the Dutch Cancer Society (2010–4832) and the Landsteiner Foundation for Blood Transfusion Research (LSBR0713).

Printing of this thesis was financially supported by Fonds Stimulans and the Jim Reekers Foundation.

Exploiting HLA-alloreactivity in TCR Gene Therapy of B Cell Malignancies

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 19 april 2017
klokke 15.00 uur

door

Lorenz Jahn

geboren te Greifswald, DDR
in 1985

Promotor:

Prof. dr. J.H.F. Falkenburg

Co-promotor:

Dr. M.H.M. Heemskerk

Leden promotiecommissie:

Prof. dr. T.N.M. Schumacher

Prof. dr. M.J. Kersten

(Universiteit van Amsterdam)

Dr. T. Mutis

(Vrije Universiteit Amsterdam)

Contents

Chapter 1	General Introduction and Aim of the Study	7
Chapter 2	Generation of CD20-specific TCRs for TCR Gene Therapy of CD20 ^{low} B-cell Malignancies Insusceptible to CD20-targeting Antibodies	35
Chapter 3	A CD22-reactive TCR from the T-cell Allorepertoire for the Treatment of Acute Lymphoblastic Leukemia by TCR Gene Transfer	71
Chapter 4	Therapeutic Targeting of the BCR Associated Protein CD79b in a TCR-based Approach Is Hampered by Aberrant Expression of CD79b	95
Chapter 5	TCR-based Therapy for Multiple Myeloma and Other B-cell Malignancies Targeting Intracellular Transcription Factor BOB1	119
Chapter 6	Summary and General Discussion	147
Appendices	Nederlandse Samenvatting	169
	Dankwoord	177
	Curriculum Vitae	178
	List of Publications	179

